See our Thought Leadership article reviewing pressures at both end of the cost spectrum and considering the likely impact on clinicians and patients. Solaris Health
While the likely premium price of upcoming genetic and cell-based therapies challenges traditional NHS funding mechanisms, the continuing influx of biosmilars is driving down the cost of biologics.
Marian Byrt looks at the challenges at both ends of the spectrum. Solaris Health
Team members at Solaris Health and RJW & partners (key healthcare agencies within the mission group) have combined on this best practice article exploring optimization of market access. Solaris Health
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out here can be applied. Solaris Health